The relationship between symptom burden and systemic inflammation differs between male and female athletes following concussion

Alex P. Di Battista 1,2*, Nathan Churchill 3, Shawn G. Rhind 1,2, Doug Richards 1,4 and Michael G. Hutchison 1,4,5

Abstract
Background: Inflammation appears to be an important component of concussion pathophysiology. However, its relationship to symptom burden is unclear. Therefore, the purpose of this study was to evaluate the relationship between symptoms and inflammatory biomarkers measured in the blood of male and female athletes following a sport-related concussion (SRC).

Results: Forty athletes (n = 20 male, n = 20 female) from nine interuniversity sport teams at a single institution provided blood samples within one week of an SRC. Twenty inflammatory biomarkers were quantitated by immunoassay. The Sport Concussion Assessment Tool version 5 (SCAT-5) was used to evaluate symptoms. Partial least squares (PLS) analyses were used to evaluate the relationship(s) between biomarkers and symptoms. In males, a positive correlation between interferon (IFN)-γ and symptom severity was observed following SRC. The relationship between IFN-γ and symptoms was significant among all symptom clusters, with cognitive symptoms displaying the largest effect. In females, a significant negative relationship was observed between symptom severity and cytokines IFN-γ, tumor necrosis factor (TNF)-α, and myeloperoxidase (MPO); a positive relationship was observed between symptom severity and MCP-4. Inflammatory mediators were significantly associated with all symptom clusters in females; the somatic symptom cluster displayed the largest effect.

Conclusion: These results provide supportive evidence of a divergent relationship between inflammation and symptom burden in male and female athletes following SRC. Future investigations should be cognizant of the potentially sex-specific pathophysiology underlying symptom presentation.

Keywords: Biomarkers, Inflammation, mTBI, Multivariate statistics, Immunity

* Correspondence: dibattista.alex@gmail.com

1 Faculty of Kinesiology & Physical Education, University of Toronto, 55 Harbord St, Toronto, ON M5S 2W6, Canada
2 Defence Research and Development Canada, Toronto Research Centre, Toronto, ON, Canada

Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Sport-related concussion (SRC) is a complex injury that can lead to somatic, cognitive, visual, sleep and emotional disturbances. Symptoms typically abate within weeks but can persist for months to years in a subset of individuals [1]. Importantly, symptom burden is a key tool for clinicians in guiding patients through the recovery process; the resolution of symptoms is a prerequisite for medical clearance and return to sport participation [1]. While biological mechanisms underlying symptom presentation following injury remain elusive, the gap in our understanding comes as no surprise, as there is significant heterogeneity in symptom presentation between individuals, both in severity and type. In addition, symptoms commonly observed following SRC have also been reported in a variety of other conditions such as polytrauma, infection, and mental illness [2–5]. In views of this, inflammation presents as a unifying concept, as it has not only been associated with concussion-like symptoms across numerous medical conditions [5], but is increasingly recognized as an important and prominent feature of concussion secondary injury [6–10]. Therefore, investigating the relationship between inflammation and symptom burden following concussion may help elucidate clinically meaningful pathophysiological mechanisms that mediate patient recovery [11, 12].

Rathbone and colleagues suggested inflammation as a common mechanism underlying the constellation of symptoms observed following concussion [5]. This assertion was made in light of the evidence linking inflammatory mediators to numerous symptoms commonly observed following concussion that are seen in medical maladies such as headache, chronic fatigue syndrome, in response to immunomodulatory medical treatments, and psychological conditions such as depression and anxiety [5]. Importantly, evidence of these relationships was commonly characterized by the presence of symptom(s) and altered blood concentrations (typically an increase) of inflammatory cytokines and/or chemokines [5].

Systemic inflammatory mediators can communicate with the central nervous system (CNS) via several mechanisms. Primary afferent and efferent nerves innervating the CNS can respond to cytokine and chemokine signaling from either the brain or periphery [13, 14], CNS-derived neuroendocrine hormones can interact with their respective receptors on circulating leukocytes in the periphery [15–18], and the blood brain barrier (BBB) permits passage of leukocytes and their mediators (cytokines and chemokines) via receptor-mediated transport, endothelial transmigration, and/or diffusion [19]. As a result of this bi-directional communicative network, peripheral inflammatory indices may be used to 1) evaluate the systemic consequences of brain-related maladies, or 2) indirectly elucidate processes occurring in the CNS. An example of this can be seen in sickness behaviour, whereby infection or illness results in fatigue, malaise, decreased appetite, lack of concentration, and feelings of depression and lethargy [20–22]. This constellation of behavioural and physiological changes is due primarily to systemic and centrally produced cytokines, namely tumor necrosis factor (TNF)-α, interleukins (IL)-1β, IL-6, and interferons (IFNs) [13, 22–26].

Our group recently identified a unique inflammatory profile in the peripheral blood of athletes following SRC that was distinct from non-head injury and characterized by elevations in the circulating chemokines monocyte chemo-attractant protein (MCP)-4 and macrophage inflammatory protein (MIP)-1β [6]. In addition, higher concentrations of MCP-1 and -4 were associated with prolonged recovery [6]. Similarly, altered inflammatory gene expression in leukocytes [8, 9], and increased brain extracellular vesicles containing TNF-α and IL-8 have also been observed in the peripheral blood of subjects following SRC [27]. Despite these findings and the strong linkage between inflammation and symptomology across numerous clinical conditions, human data characterizing the potential role of inflammation on symptom burden following concussion is scarce. Su and colleagues observed that a higher concentration of the circulating inflammatory index C-reactive protein (CRP) was associated with a greater symptom burden in subjects in the months following mTBI [28]. Likewise, Nitta and colleagues recently identified a positive relationship between serum interleukin IL-6 concentrations and symptom duration following SRC [10]. While this is intriguing, the relationship between concussion symptoms and inflammation has yet to be evaluated across the range of inflammatory mediators previously studied in TBI [6, 29–31]. Furthermore, probable sex differences have not been accounted for; despite the profound differences observed in male versus female immune responses as a consequence of genetic, environment and hormonal influences [32, 33], few studies evaluating inflammation stratify their cohorts by sex [33].

The present study builds upon prior works by examining the relationships between symptom burden and inflammation in males and females following SRC. We hypothesized that symptoms reported in the subacute period following injury would correlate with systemic inflammatory cytokines and chemokines, and that this relationship would differ between males and females. This hypothesis was evaluated in a cohort of university-level athletes assessed within seven days post-injury using a set of multivariate PLS models. These analyses were performed with the goal of improving our understanding of how inflammation may mediate symptom burden in males and females following SRC.
Results

Athlete characteristics and biomarker values

Athlete demographics, symptoms, and recovery time can be found in Table 1, and participant recruitment and enrollment information can be found in Fig. 1. There were no significant differences in any of the clinical characteristics between male and female athletes; notably, total symptom reporting ($p = 0.522$), symptom severity ($p = 0.763$), and the median days to medical clearance ($p = 0.513$) were similar. Male and female biomarker values following SRC can be observed in Table 2. While there were no significant differences in biomarker concentrations between males and females after correcting for multiple comparisons, uncorrected MCP-1 (66.6 vs. 53.3 pg/mL, $p = 0.023$), MIP-1B (43.6 vs 31.8 pg/mL, $p = 0.007$) and Eotaxin (94.2 vs. 81 pg/mL, $p = 0.028$) concentrations were significantly lower in females compared to males, and IP-10 (179.4 vs 207.7 pg/mL, $p = 0.026$) concentrations were significantly higher in females compared to males.

Relationship between symptoms and days to recovery

A significant, large correlation between calculated symptom severity and days to recovery (i.e., medical clearance) was observed for both males (mean rho = 0.73, $p < 0.001$, BSR = 6.8) and females (mean rho = 0.63, $p < 0.001$, BSR = 3.5).

Relationship between inflammatory biomarkers and symptoms

PLS plots showing the relationship between symptom severity and inflammatory biomarkers following SRC can be seen in Fig. 2. The plot depicts biomarker loadings which describe their weighted contribution towards symptom severity, with effect sizes determined via
bootstrap ratios (BSR) (see methods section). In male athletes, symptom severity significantly positively correlated with blood concentrations of IFN-γ \((p = 0.04, \text{ BSR} = 2)\). Conversely, in female athletes, symptom severity negatively correlated with IFN-γ \((p = 0.01, \text{ BSR} = 2.6)\), MPO \((p = 0.008, \text{ BSR} = 2.6)\), and TNF-α \((p = 0.001, \text{ BSR} = 3.2)\), and positively correlated with MCP-4 \((p = 0.04, \text{ BSR} = 2.1)\) (Fig. 2). Cross-correlation \((R^2)\) of the PLS model containing symptom severity and inflammatory biomarkers was 0.07 \((95\% \text{ CI} = 0.04–0.1)\) in males and 0.29 \((95\% \text{ CI} = 0.24–0.35)\) in females.

PLS plots showing the correlation between symptom clusters and inflammatory biomarkers in male and female athletes following SRC can be found in Figs. 3 & 4. Latent variables are plotted, describing the two most relevant structures describing the relationship between symptoms and biomarkers. In male athletes, there were two latent variables describing 86% of the covariance between symptoms and biomarkers. The first latent variable (LV) (explaining 61% of covariance between symptoms and biomarkers) was characterized by a significant positive correlation between all symptom clusters and IFN-γ \((p = 0.03, \text{ BSR} = 2.1)\);

### Table 2: Inflammatory biomarker concentrations in athletes with SRC

| Marker | Males (n = 20) | Females (n = 20) | \(p\) value | FDR |
|--------|----------------|-----------------|-------------|-----|
| IFN-γ  | 3.1 (2.5–5.0)  | 4.1 (2.5–5.9)   | 0.326       | no  |
| TNF-α  | 1.7 (1.4–2.2)  | 1.5 (1.3–1.9)   | 0.305       | no  |
| MPO (ng/mL) | 13.4 (7.5–21.4) | 9.0 (7.9–11.4) | **0.018**   | no  |
| IL-8   | 2.0 (1.7–2.6)  | 2.0 (1.3–2.4)   | 0.149       | no  |
| MCP-1  | 66.6 (57.6–73.5)| 53.3 (45.8–65.4)| 0.090       | no  |
| MCP-4  | 275 (205–324)  | 230 (189–291)   | 0.505       | no  |
| MIP-1β | 43.6 (31.5–53.6)| 31.8 (25.0–40.0)| **0.021**   | no  |
| IP-10  | 179.4 (133.2–219.8)| 207.7 (166.4–294.8)| **0.016**  | no  |
| TARC   | 72.7 (44.3–94.9)| 55.1 (48.2–67.5)| 0.061       | no  |
| Eotaxin| 94.2 (82.2–127.5)| 81.0 (66.0–94.8)| **0.028**   | no  |

All values reported as the median and interquartile range in pg/mL, unless otherwise stated.

P values are derived from bootstrap ratios (BSR) of the mean difference between biomarker values in male and female athletes, corrected at FDR = 0.05.

In the case of deviations from normality, the BSR was calculated from the winsorized mean difference.

Bold values indicate pre-corrected \(p < 0.05\)

### Fig. 2: Correlation between inflammatory biomarkers and symptom severity in male and female athletes following a sport-related concussion.

Eotaxin, interferon (IFN)-γ, interleukin (IL)-8, interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, −4, macrophage inflammatory protein (MIP)-1β, Myeloperoxidase (MPO), thymus and activation-regulated chemokine (TARC), and tumor necrosis factor (TNF)-α. Plots show the contributions of biomarkers measured in the subacute period following injury towards symptom severity in male \((n = 20)\) and female \((n = 20)\) athletes. Bars represent variable loadings and the standard error derived from bootstrapped resampling (5000 iterations, male = red, female = green). Significance is displayed at \(p < 0.05^*\), \(p < 0.01^{**}\) and \(p < 0.001^{***}\)
cognitive symptom cluster displayed the greatest effect size ($p < 0.001$, BSR = 5.5), while the fatigue symptom cluster displayed the lowest ($p = 0.03$, BSR = 2.1) (Fig. 3a). The second LV, (explaining 25% of covariance) was characterized by a positive correlation between symptoms of emotion ($p < 0.001$, BSR = 3.9) and IL-8 ($p = 0.03$, BSR = 2.2), MCP-4 ($p < 0.001$, BSR = 3.5), and thymus and activation-regulated chemokine (TARC) ($p < 0.001$, BSR = 3.7) (Fig. 3b).

In female athletes, there were two latent variables describing 79% of the covariance between symptoms and biomarkers. The first LV (explaining 55% of covariance) was characterized by a negative relationship between symptom clusters and inflammatory biomarkers: Higher symptoms (all clusters) were negatively correlated with TNF-α ($p = 0.01$, BSR = 2.6), IFN-γ ($p = 0.01$, BSR = 2.4) and myeloperoxidase (MPO) ($p = 0.02$, BSR = 2.3). However, a positive correlation was observed between symptoms (all clusters) and MCP-4 ($p = 0.04$, BSR = 2.0). The largest effects were seen with somatic symptoms ($p < 0.001$, BSR = 6.8), while the smallest effects were seen with cognitive symptoms ($p = 0.009$, BSR = 2.6) (Fig. 4a). In the second LV (explaining 24% of covariance), while there was a relationship between cognitive symptoms ($p = 0.03$, BSR = 2.1) and biomarkers, there were no significant associations with individual inflammatory biomarker loadings (Fig. 4b).

**Discussion**

In this study, we identified a significant relationship between symptom burden and systemic inflammation following SRC, with differences between males and females. Within the first week of injury, reported symptom severity was inversely correlated with inflammatory cytokines in the peripheral blood of female athletes, yet positively
Importantly, these differences were noted despite male and female groups having a comparable symptom burden and time to recovery. This suggests that inflammation is an important and clinically relevant component of secondary injury following SRC but may present differently in males and females.

We observed greater symptom burden was associated with lower concentrations of the classical inflammatory cytokines IFN-γ and TNF-α, and the innate immune function marker MPO in female athletes following SRC; a positive relationship was observed with the chemokine MCP-4. The somatic symptom cluster displayed the greatest effect, while the cognitive cluster displayed the lowest, and the overall relationship between symptoms and inflammation was comparatively more generalizable in females than males (PLS cross-correlation $R^2 = 0.07$ in males, $R^2 = 0.29$ in females). While we hypothesized a sex-difference in the relationship between inflammation and symptom burden following injury, the direction of the association observed in female athletes is seemingly non-intuitive. The preponderance of evidence linking concussion symptoms to inflammation suggests a positive relationship (for review see [5]), and females typically have a greater inflammatory response to challenge compared to males [33]. However, in a recent meta-analysis evaluating peripheral chemokine and cytokines in depression, while the majority of studies found positive relationships, lower concentrations of TNF-α and IFN-γ were also observed (for review see [34]). Furthermore, a number of perturbations to inflammatory genes in peripheral leukocytes have been observed following SRC, displaying both upregulation and downregulation [8, 9]. Hence, it is possible that both the complexity of the inflammatory response to concussion as well as potentially divergent responses in males
and females contribute to these mixed findings. In addition, it is conceivable that the menstrual cycle may have had an effect; immune function can vary widely with hormonal changes during the menstrual cycle, with potential immunosuppression in the luteal phase [35–37]. While it is still unclear why we observed that symptom burden was correlated with lower levels of inflammatory cytokines in females following SRC, the results of this investigation provide supportive evidence that inflammation following concussion should not be looked at without dichotomizing groups by sex.

As opposed to females, in the current study symptom severity was positively correlated with blood concentrations of IFN-γ in male athletes following SRC. This observation is generally supported by literature that has shown a positive association between the family of IFN proteins and symptoms such as headache, fatigue, irritability, hostility, and depression [34, 38, 39] in numerous maladies. While we found IFN-γ was associated with all symptom clusters, cognitive symptoms displayed the highest effect; in females cognitive symptoms displayed the lowest effect. Furthermore, we observed a small, stable effect in males between the emotion symptom cluster and the chemokines IL-8, MCP-4 and TARC. These mediators are primarily responsible for neutrophil [40], monocyte [40] and lymphocyte chemotraction [41], respectively, and chemokines have been broadly implicated in leukocyte trafficking to the brain following TBI [29, 40, 42, 43]; indeed, higher concentrations of IL-8 in the blood acutely following severe TBI have been correlated with unfavorable outcome [30]. Regarding symptom burden, although chemokines have been broadly implicated in depression, the specific relationship(s) between MCP-4, IL-8 and TARC and the behaviours and mood states comprising the “emotion” symptom cluster in the current study (emotional, irritability, sadness, nervous/anxious) are not well defined. Furthermore, it is important not to overstate this relationship, as these findings were found on the second LV comprising only 25% of the covariance in the PLS model and are comparatively small relative to the magnitude of the relationship observed between symptoms and IFN-γ. Taken together, further research is warranted both to replicate these findings and to investigate the mechanisms mediating the relationship between inflammation and symptom burden in male athletes following SRC.

The mechanism(s) underlying the relationship observed in the current study between symptom burden and inflammation following SRC are unknown. However, given the strong influence of the neuroendocrine system on inflammation [44–46], its role in both brain injury [9, 17, 47–49] and related symptomology [50–53] along with the differences in neuroendocrine biology between males and females [54–56], it is plausible that the stress-immune axis mediates the relationship between symptoms and inflammation following concussion. The two major arms of the body's stress system, the sympathetic nervous system (SNS) and the hypothalamic pituitary adrenal (HPA) axis can augment the immune system in numerous ways. For example, the HPA-axis, through the actions of glucocorticoids can have strong immunosuppressive effects [57–59], while the SNS can be pro- or anti-inflammatory depending on the nature of the stimulus and subsequent catecholamine-adrenergic receptor pairing [15, 32, 31], and have recently observed that neuroendocrine hormones in the blood following sport concussion are associated with both symptom burden and time to medical clearance [60]. In support of the latter, Merchant-Borna and colleagues observed a change in lymphocyte transcription of genes regulating HPA-axis activity and inflammation at seven days post-SRC [9]. However, the complex interactions between sex, neuroendocrine-immune signalling, their effect on symptom burden, and the temporal shifts in these processes that likely occur to restore homeostasis throughout recovery are not understood. Lastly, given the pleiotropy, biological redundancy, and dynamic nature of the inflammatory response, it is difficult to control for the vast number of confounds when conducting a human study. As a result, a normative healthy group can be a potential source of biological noise in statistical analyses. The purposeful exclusion of a healthy control sample in the current study allowed for a direct evaluation of the relationship between symptom burden and inflammation post-injury. However, this approach also allows for the possibility that pre-injury biological conditions and/or phenotypes affecting the inflammatory system or that contribute to symptom burden, impacted our findings. In view of this, in the current study we observed a relationship between inflammatory biomarkers and concussion history in male athletes following SRC (Supplementary Fig. 1), and it is unclear how this may have impacted post-injury inflammation. Hence, future studies aimed at uncovering the intricacies of these interrelationships, including both pre- and post-injury biology and the potential mediating effect of concussion history, are necessary.

The results of the study must be interpreted within the context of its limitations. While the sport concussion assessment tool (SCAT) symptom profile is a well-studied and useful tool utilized by clinicians and concussion researchers, investigation into specific symptoms may have benefited from more directed measures. For example, clinical screening tools for depression (i.e., the Beck Depression Inventory) and anxiety disorders (i.e., the general anxiety disorder questionnaire-7) may have provided utility to the current analysis, as would physiological evaluations of sleep (i.e., heart rate variability monitoring), and more objective neuropsychological evaluations of cognitive function. Furthermore, a larger study sample would have permitted a greater degree of
subgroup analysis (i.e., prior concussion history, menstrual cycle in females), and baseline evaluations would have allowed for the consideration of potential pre-injury differences in symptom presentation between males and females [61, 62]. Finally, a more narrow and acute sample timepoint may have helped capture a more profound inflammatory response to injury; despite there being no relationship between the time elapsed from SRC to blood draw and either symptom severity (spearman rho = 0.05, \( p = 0.75 \)), or time to medical clearance (spearman rho = 0.17, \( p = 0.29 \)), we observed a correlation between inflammatory biomarkers and days from SRC to blood draw (Supplementary Fig. 2). Lastly, our study focused on evaluating the relationship between symptom burden and systemic inflammation at a single time point post-injury, therefore follow-up studies are required to characterize this relationship throughout recovery; given our groups’ prior findings of persistent symptoms at medical clearance utilizing both advanced neuroimaging [63, 64] and blood biomarkers [65], it remains unclear how symptom burden tracks biological recovery.

Conclusion
Symptom burden is associated with unique inflammatory profiles in male and female athletes following SRC. Symptom severity is associated with elevated blood concentrations of IFN-\( \gamma \) in males, yet lower levels of IFN-\( \gamma \), TNF-\( \alpha \), and MPO in females: the relationship between symptoms and inflammation appears to be more generalizable in females. Future investigations into inflammation as a clinically meaningful secondary injury process following concussion should not ignore the potentially divergent pathophysiology underlying symptom presentation in males and females.

Methods
Participants
Participant eligibility and enrolment information are visualized in Fig. 1. From August 2015 – February 2018, 113 athletes with SRC were eligible for study enrollment. From this, 70 athletes were enrolled, and 49 consented to blood draw. Due to an inability to draw blood (\( n = 4 \)), medications that interfered with inflammatory processes (\( n = 2 \)), and an absence of SCAT symptom information (\( n = 3 \)), 40 interuniversity athletes with a clinician diagnosed SRC were enrolled (\( n = 20 \) male (M), \( n = 20 \) female (F)) from nine sport teams: basketball (M & F), field hockey (F), football (M), ice hockey (M & F), lacrosse (M & F), mountain biking (F), rugby (M & F), soccer (F), volleyball (M & F). This cohort was analyzed in a previously published study by our group [6]. Concussion diagnosis and medical clearance decisions were made by a staff physician at the university sport medicine clinic in accordance with the Concussion in Sport Group guidelines [1]. Prior to enrollment, all participants provided written informed consent; all study procedures were in accordance with the declaration of Helsinki, and approved by the Health Science Research Ethics Board, University of Toronto (protocol reference # 27958).

Blood biomarkers
Blood was sampled from athletes within a range of 2–7 days following an SRC (males, median = 4 days; females, median = 5 days). Athletes were excluded if they were taking medications other than birth control, or if they were currently symptomatic as a result of a known infection, illness or seasonal allergies. Venous blood was drawn into a 10-mL K2EDTA tube and was equilibrated for approximately one hour at room temperature before a two min centrifugation using a PlasmaPrep 12™ centrifuge (Separation Technology Inc., FL, USA). Plasma supernatant was then aliquoted and frozen at −80 °C until analysis.

Nineteen cytokines and chemokines were analyzed by immunoassay using Meso Scale Diagnostics 96-well MULTI-SPOT™ technology: interferon (IFN)-\( \gamma \), interleukin (IL)-1\( \beta \), –2, –4, –6, –8, –10, –12p70, –13, tumor necrosis factor (TNF)-\( \alpha \), eotaxin, eotaxin-3, interferon gamma-induced protein (IP)-10, monocyte chemotactic protein (MCP)-1, –4, macrophage-derived chemokine (MDC), macrophage inflammatory protein (MIP)-1\( \alpha \), –1\( \beta \), and thymus and activation-regulated chemokine (TARC). Myeloperoxidase (MPO) was run as a single-plex assay. All assays were run according to manufacturer’s instructions, with individual samples run in duplicate.

Symptoms
On the day of the blood draw, athletes’ concussion symptoms were ascertained via a 22-item post-concussion symptom scale using a seven-point Likert rating as part of the Sport Concussion Assessment Tool (SCAT). The SCAT is the most widely used tool to assist in the diagnosis, management, and prognosis of individuals with concussion [1], and has shown reliability and validity for the assessment of both symptom presence and severity [66, 67]. A total symptom score was obtained by summing the presence or absence of each symptom irrespective of severity, with a maximum value of 22; symptom severity was evaluated by summing the rated symptom score for each symptom. In addition, four distinct symptom clusters were obtained by combining and summing the scores of SCAT symptoms related to somatic complaints (headache, pressure in head, neck pain, nausea/vomiting, dizziness, blurred vision, balance problems, sensitivity to light, sensitivity to noise), cognition (feeling slowed down, feeling in a fog, don’t feel right, difficulty concentrating, difficulty remembering, confusion), sleep (fatigue/low energy, drowsiness, trouble...
falling asleep), and emotion (more emotional, irritability, sadness, nervous/ anxious). This approach has been previously employed by our group [6, 68].

**Statistical analysis**

Prior to statistical analysis, we applied a previously published set of biomarker detection criteria [6], retaining only biomarkers that contained individual values for > 80% of subjects per biomarker. Biomarker values were removed if they 1) did not fall within the manufacturer provided limits of detection, or 2) displayed a > 25% coefficient of variation between individual sample replicates. Hence, 10 of 20 inflammatory biomarkers satisfied these criteria and were evaluated in the current study. See Supplementary Table 1 for biomarker detection data in both male and female participant groups. All variables (biomarkers and symptoms) were tested for deviations from normality by calculating sample skewness and kurtosis, with empirical p-values obtained by comparison against a simulated null distribution (random Gaussian noise, 1000 sampled sets). In males, skewness ranged from 0 (p = 0.448) to 1.5 (p = 0.003), and kurtosis ranged from 3.2 (p = 0.721) to 9.4 (p = 0.001). In females, skewness ranged from −0.9 (p = 0.949) to 2.2 (p < 0.001), and kurtosis ranged from 3.1 (p = 0.796) to 10.6 (p < 0.001). Hence, prior to all statistical comparisons, missing values were imputed separately in male and female subjects using the variable median, followed by rank transformation for symptom variables and a two-tailed winsorization (10%) of biomarkers that significantly deviated from normality.

Univariate comparisons of demographic variables and biomarkers between male and female athletes following SRC (Tables 1 & 2) were evaluated by calculating the mean differences, followed by bootstrapping of the mean difference scores (1000 resamples) to obtain standardized effect size in terms of bootstrap ratios (BSR; mean / standard error) and empirical p values based on the bootstrap estimates of the standard error, which were corrected at a false discovery rate (FDR) of 0.05. Univariate correlation analyses were conducted between calculated symptom severity and days to recovery via Spearman correlation with bootstrapping used to obtain BSRs and empirical p values.

The primary aim of the study was to test for associations between symptom reporting and inflammatory biomarker profiles in male and female athletes following SRC using a statistical framework designed to elucidate the potential complexity of these relationships, and without the potential confounds that would arise by including a comparison to a healthy athlete population. To accomplish this, a partial least squares (PLS) correlation analysis was employed [69]. PLS is a multivariate data reduction technique that creates orthogonal latent variables describing the maximal covariance between a set of predictor (biomarkers) and response (symptoms) variables [69]. In the current study, PLS was used in a bootstrap resampling framework (5000 iterations) to generate sets of variable loadings (i.e., weighted combinations of biomarkers / symptom clusters), along with corresponding BSRs and empirical p-values based on the bootstrap estimates of the standard error. For analyses evaluating the correlation between inflammatory biomarkers and calculated symptom severity, an out-of-sample, leave-two-out cross correlation (R²) value was calculated on the PLS model. PLS plots represent the mean and standard deviation (SD) of the resamples for each variable. All statistical analyses and graphs were completed with R (RStudio, version 1.1.456, Boston, United States).

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12865-020-0339-3.

**Additional file 1:** Figure S1. Correlation between inflammatory biomarkers and concussion history in male and female athletes following sport-related concussion. Eotaxin, interferon (IFN)-γ, interleukin (IL)-8, interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1B, Myeloperoxidase (MPO), thymus and activation-regulated chemokine (TARC), and tumor necrosis factor (TNF)-α. Plots show the variable loadings in male (n = 20) and female (n = 20) athletes subacutely following a sport-related concussion, depicting their correlation to concussion history. Bars represent variable loadings and the standard error derived from bootstrapped resampling (5000 iterations, male = red, female = green). Significance is displayed at p < 0.05 *, p < 0.01 **,  and p < 0.001 ***.

**Additional file 2:** Figure S2. Correlation between inflammatory biomarkers and days elapsed between sport-related concussion and blood draw. Eotaxin, interferon (IFN)-γ, interleukin (IL)-8, interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1B, Myeloperoxidase (MPO), thymus and activation-regulated chemokine (TARC), and tumor necrosis factor (TNF)-α. Plots show the variable loadings in male (n = 20) and female (n = 20) athletes subacutely following a sport-related concussion, depicting their correlation to the number of days between injury and blood draw. Bars represent variable loadings and the standard error derived from bootstrapped resampling (5000 iterations, male = red, female = green). Significance is displayed at p < 0.05 *, p < 0.01 **,  and p < 0.001 ***.

**Additional file 3:** Table S1. Biomarker Detectability.

**Abbreviations**

BBB: Blood brain barrier; BSR: Bootstrap ratio; CI: Confidence interval; CNS: Central nervous system; CRP: C-reactive protein; F: Female; HPA: Hypothalamic pituitary adrenal; IFN: Interferon; IL: Interleukin; IP: Interferon gamma induced protein; LV: Latent variable; M: Male; MCP: Monocyte chemoattractant protein; MDC: Macrophage-derived chemokine; MIP: Macrophage inflammatory protein; MPO: Myeloperoxidase; PCS: Post-concussion syndrome; PLS: Partial least squares; SCAT: Sport concussion assessment tool; SNS: Sympathetic nervous system; SRC: Sport-related concussion; TARC: Thymus and activation regulated chemokine; TBI: Traumatic brain injury; TNF: Tumor necrosis factor

**Acknowledgements**

The authors would like to acknowledge Miss Maria Shiu and Miss Katy Moes of Defense Research and Development Canada for their contributions to this manuscript. This study was approved by the Canadian Armed Forces Surgeon General’s Health Research Program. In accordance with the Department of National Defence policy, the paper was reviewed and
approved for submission without modification by the DROC Publications Office.

Authors' contributions
All authors conceived and designed the study. AD and SR collected the data. AD, NC and MH analyzed the data. AD, NC, MH and DR wrote the manuscript, all authors revised the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by the Canadian Institute of Military and Veterans Health Research and Defence Research and Development Canada.

Availability of data and materials
All data is available upon author request.

Ethics approval and consent to participate
Prior to enrollment, all participants provided written informed consent; all ethics approval and consent to participate. All data is available upon author request.

Availability of data and materials
All data is available upon author request.

Competing interests
The authors declare no competing interests.

Author details
1Faculty of Kinesiology & Physical Education, University of Toronto, 55 Harbord St, Toronto, ON M5S 2W6, Canada. 2Defence Research and Development Canada, Toronto Research Centre, Toronto, ON, Canada. 3Neuroscience Program, Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, Toronto, ON, Canada. 4David L. MacIntosh Sport Medicine Clinic, Faculty of Kinesiology & Physical Education, University of Toronto, Toronto, ON, Canada. 5Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, Toronto, ON, Canada.

Received: 31 October 2019 Accepted: 26 February 2020

Published online: 12 March 2020

References
1. McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, Cantu RC, Cassidy E, Echemendia RJ, Castellani RJ, et al. Consensus statement on concussion in sport—the 5th international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med. 2017;51(11):838–47.
2. Cassidy JD, Cancelliere C, Carroll LJ, Cote P, Hincapie CA, Holm LW, Hartvigsen J, Donovon J, Nygren-de Bousard C, Kristman VL, et al. Systematic review of self-reported prognosis in adults after mild traumatic brain injury: results of the international collaboration on mild traumatic brain injury prognosis. Arch Phys Med Rehabil. 2014;95(3 Suppl):S132–5.
3. Meares S, Shores EA, Taylor AJ, Batchelor J, Bryant RA, Baguley IJ, Chapman J, Gurka J, Dawson K, Capon L, et al. Mild traumatic brain injury does not predict acute postconcussion syndrome. J Neurol Neurosurg Psychiatry. 2008;79(3):300–6.
4. Meares S, Shores EA, Taylor AJ, Batchelor J, Bryant RA, Baguley IJ, Chapman J, Gurka J, Marosszeky JE. The prospective course of postconcussion syndrome: the role of mild traumatic brain injury. Neuropsychology. 2011;25(4):454–65.
5. Rathbone AT, Tharmaratnam S, Jiang S, Rathbone MP, Kumhare DA. A review of the neuro- and systemic inflammatory responses in post concussion symptoms: introduction of the "post-inflammation brain injury syndrome". PIRS. Brain Behav Immun. 2015;46:1–16.
6. Di Battista AP, Churchill N, Rhind SG, Richards D, Hutchison MG. Evidence of a distinct peripheral inflammatory profile in sport-related concussion. J Neurol Neurosurg Psychiatry. 2019;16(1):17.
7. Ebnet SE, Jensen P, Ozener B, Armand S, Svaer C, Stenbaek DS, Moeller K, Dyssegaard A, Thomsen G, Steinmetz J, et al. Molecular imaging of neuroinflammation in patients after mild traumatic brain injury: a longitudinal (123I) ICLINDE single photon emission computed tomography study. Eur J Neurol. 2019;26(12):1426–32.
8. Gill J, Merchant-Borna K, Lee H, Livingston WS, Olivera A, Cashon A, Wang D, Bazarian JJ. Sports-related concussion results in differential expression of nuclear factor-kappaB pathway genes in peripheral blood during the acute and subacute periods. J Head Trauma Rehabil. 2016;31(4):269–76.
9. Merchant-Borna K, Lee H, Wang D, Bogner V, van Griesven M, Gill J, Bazarian JJ. Genome-wide changes in peripheral gene expression following sports-related concussion. J Neurotrauma. 2016;33(17):1576–85.
10. Nitta ME, Savitz J, Nelson LD, Teague TK, Hoenle JB, McCrea MA, Meier TB. Acute elevation of serum inflammatory markers predicts symptom recovery after concussion. Neurology. 2019;93(5):e497–507.
11. Chancelier SE, Franz ES, Minerva OV, Goldstein LE. Pathophysiology of concussion. Semin Pediatr Neurol. 2019;30:14–25.
12. Giza C, Geczko T, Prins ML. Concussion: pathophysiology and clinical translation. Handb Clin Neurol. 2018;158:51–61.
13. Dantzner R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001;933(1):222–34.
14. Filliano AJ, Gadani SP, Kipnis J. How and why do T cells and their derived cytokines affect the injured and healthy brain? Nat Rev Neurosci. 2017;18(6):375–84.
15. Blenkov II, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595–638.
16. Esterov D, Greenwald BD. Autonomic dysfunction after mild traumatic brain injury. Brain Sci. 2017;7(8):100.
17. Molae AM, Maguire J. Neuroendocrine abnormalities following traumatic brain injury: an important contributor to neuropsychiatric sequelae. Front Endocrinol (Lausanne). 2018;9:176.
18. Vizi ES, Blenkov II. Nonsynaptic noradrenaline release in neuro-immune responses. Acta Biol Hung. 2002;53(1–2):229–44.
19. Takeshita Y, Ranshoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev. 2012;248(1):228–39.
20. Dantzner R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.
21. Harrison NA, Brydon L, Walker C, Gray MA, Skeptoe A, Dolan RJ, Critchley HD. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry. 2009;66(5):415–22.
22. Korsman JP, Parret F, Dantzner R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002;25(3):154–9.
23. Dantzner R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. 2001;15(1):7–24.
24. Dantzner R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29(2):247–64.
25. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503–8.
26. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Monag A, Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5):445–52.
27. Kawata K, Matsuhashi M, Aldert R. A preliminary report on brain-derived extracellular vesicle as novel blood biomarkers for sport-related concussions. Front Neurol. 2018;9:239.
28. Su SH, Xu W, Li M, Zhang L, Wu YF, Yu F, Hai J. Elevated C-reactive protein levels may be a predictor of persistent unfavourable symptoms in patients with mild traumatic brain injury: a preliminary study. Brain Behav Immun. 2014;38:1111–7.
29. Semple BD, Bye N, Rancan M, Ziebell JM, Morgant-Kossmann MC. Role of CC12 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CC12/−/− mice. J Cereb Blood Flow Metab. 2010;30(4):769–82.
30. Di Battista AP, Rhind SG, Hutchison MG, Hassan S, Shiu MY, Inaba K, Topolovec-Vranic J, Neto AC, Rizzoli SB, Baker AJ. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflammation. 2016;13:40.
31. Di Battista AP, Rizzoli SB, Leijnies B, Min A, Shiu MY, Peng HT, Baker AJ, Hutchison MG, Churchill N, Inaba K, et al. Symptomatic activation is associated with acute traumatic coagulopathy and Endotheliopathy in isolated brain injury. Shock. 2016;46(3 Suppl 1):906–13.
32. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008;8(9):737–44.
33. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38.
